You are here

Pharmaceutical Industry Dispatches Army of Lobbyists to Block Generic COVID-19 Vaccines

Pharmaceutical Industry Dispatches Army of Lobbyists to Block Generic COVID-19 Vaccines --New lobbying disclosures show over 100 drug lobbyists working to defeat the IP waiver request at the WTO. | 23 April 2021 | The pharmaceutical industry is pouring resources into the growing political fight over generic coronavirus vaccines. Newly filed disclosure forms from the first quarter of 2021 show that over 100 lobbyists have been mobilized to contact lawmakers and members of the Biden administration, urging them to oppose a proposed temporary waiver on intellectual property rights by the World Trade Organization that would allow generic vaccines to be produced globally. Pharmaceutical lobbyists working against the proposal include Mike McKay, a key fundraiser for House Democrats, now working on retainer for Pfizer, as well as several former staff members to the U.S. Office of Trade Representative, which oversees negotiations with the WTO. Several trade groups funded by pharmaceutical firms have also focused closely on defeating the generic proposal, new disclosures show.